Carysil Limited

BSE:524091 Lagerbericht

Marktkapitalisierung: ₹34.3b

Carysil Zukünftiges Wachstum

Future Kriterienprüfungen 3/6

Carysil wird ein jährliches Gewinn- und Umsatzwachstum von 17.4% bzw. 15.5% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 17.3% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17.4% betragen.

Wichtige Informationen

17.4%

Wachstumsrate der Gewinne

17.35%

EPS-Wachstumsrate

Building Gewinnwachstum21.4%
Wachstumsrate der Einnahmen15.5%
Zukünftige Eigenkapitalrendite17.43%
Analystenabdeckung

Low

Zuletzt aktualisiert22 May 2026

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Narrative-Update • Jun 18

524091: Subsidiary Simplification And Dividend Plans Will Shape Future Share Performance

Analysts have kept their fair value estimate for Carysil steady at ₹1,270.50, with the small adjustments in discount rate, revenue growth, profit margin and future P/E assumptions leading to only a marginal refinement in the overall price target narrative. What’s in the News for Carysil Board meeting on May 20, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on equity shares for the financial year ended March 31, 2026.
Narrative-Update • Jun 02

524091: Subsidiary Simplification And Dividend Policy Will Support Future Upside

Carysil’s analyst price target is unchanged at ₹1,270.5, as analysts balance slightly adjusted assumptions for discount rate, revenue growth, profit margins and future P/E to arrive at the same fair value estimate. What's in the News A board meeting is scheduled for May 20, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider a final dividend on the equity shares for FY 2025-26.
Narrative-Update • May 17

524091: Subsidiary Rationalisation And QIP Extension Will Support Future Upside

Carysil’s analyst price target has changed from ₹1,205.67 to ₹1,270.50 as analysts incorporate slightly adjusted assumptions for the discount rate, revenue growth, profit margin and future P/E, resulting in a modestly higher fair value estimate. What's in the News A board meeting is scheduled on May 20, 2026 to consider and approve audited standalone and consolidated financial results for the quarter and year ended March 31, 2026, and to consider and recommend a final dividend, if any, on equity shares for the financial year ended March 31, 2026 (Key Developments).
Narrative-Update • Apr 28

524091: Subsidiary Rationalisation And QIP Timeline Extension Will Support Future Upside

Analysts have kept Carysil’s fair value estimate broadly unchanged at about ₹1,205.67, with only small tweaks to the discount rate, revenue growth, profit margin and future P/E assumptions, leading to a steady overall price target narrative. What's in the News Board meeting scheduled on Mar 20, 2026 at 15:00 IST to review the appointment of an internal auditor and a cost auditor.
Narrative-Update • Apr 12

524091: Subsidiary Closures And QIP Utilisation Decisions Will Support Future Upside

Analysts have kept their average price target for Carysil broadly steady at around ₹1,205.67, citing largely unchanged assumptions on revenue growth, profit margins and future P/E, with only minor adjustments to the discount rate in their models. What's in the News A board meeting is scheduled on Feb 04, 2026 to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (Key Developments).
Narrative-Update • Mar 28

524091: Upcoming Board Decisions On Subsidiary Closures Will Support Future Upside

Analysts have kept their fair value estimate for Carysil steady at ₹1,205.67 per share, with only minimal tweaks to inputs such as the discount rate, revenue growth outlook, profit margin assumptions and future P/E. This reflects a view that recent data does not materially change the stock’s underlying valuation story.
Narrative-Update • Mar 11

524091: Upcoming Board Results And Stable Assumptions Will Support Future Upside

Analysts have maintained their fair value estimate for Carysil at ₹1,205.67 per share, while making refinements to inputs such as a slightly lower discount rate and minor adjustments to revenue growth, profit margin, and future P/E expectations to reflect updated assumptions in their models. What's in the News Carysil has scheduled a board meeting for February 4, 2026 to review and approve unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative-Update • Feb 25

524091: Upcoming Results And Steady Assumptions Will Support Future Upside

Analysts have maintained their fair value estimate for Carysil at ₹1,205.67 per share, making only minor model adjustments, such as a slightly higher discount rate and a modestly higher assumed future P/E multiple. These changes together leave the overall price target unchanged.
Narrative-Update • Feb 11

524091: Upcoming Results And Improved Margin Outlook Will Support Future Upside

Analysts have nudged their fair value estimate on Carysil higher from ₹1,165 to about ₹1,206, citing updated assumptions on discount rate, revenue growth, profit margins and future P/E that better reflect their current expectations for the business. What's in the News Carysil has scheduled a board meeting on February 4, 2026, to consider and approve its unaudited standalone financial results for the quarter and nine months ended December 31, 2025 (Key Developments).
Narrative-Update • Jan 27

524091: Steady Outlook And Upcoming Results Date Will Support Future Upside

Analysts have kept their fair value estimate for Carysil steady at ₹1,165, with only marginal tweaks to inputs like the discount rate and assumed future P/E. This reflects fine tuning of their models rather than a change in their core view.
Narrative-Update • Jan 10

524091: Steady Assumptions And Upcoming Results Will Support Future Upside

Analysts have maintained their price target for Carysil at ₹1,165 per share. This unchanged view mainly reflects consistent assumptions regarding fair value, discount rate, revenue growth, profit margin and future P/E.
Narrative-Update • Dec 15

524091: Capacity Expansion Will Drive Future Earnings Momentum

Analysts have modestly raised their price target on Carysil to ₹1,165 per share (from ₹1,165), reflecting slightly higher discount rate and valuation assumptions while keeping long term growth and margin expectations broadly unchanged. What's in the News Carysil has scheduled a board meeting on November 10, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (company filing).
Narrative-Update • Dec 01

524091: Capacity Expansion And Dividend Increase Will Drive Upward Momentum

Analysts have raised their price target for Carysil from ₹1,130.33 to ₹1,165.00, citing improved forecasts for revenue growth and profit margins that support a higher fair value estimate. What's in the News A board meeting is scheduled for November 10, 2025 to consider and approve unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Board Meeting).
Narrative-Update • Nov 16

524091: New Capacity Expansion And Dividend Increase Set To Shape Outlook

Analysts have increased Carysil's fair value estimate from ₹1,039 to ₹1,130.33, citing modest changes in growth forecasts and profit margins, which support a slightly higher valuation target. What's in the News Carysil's board will meet on November 10, 2025, to consider and approve the unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025 (Board Meeting).
Narrative-Update • Aug 18

Global Kitchen Upgrades And Market Expansion Will Transform Industry

Carysil’s consensus price target has been raised to ₹1039, reflecting a notable improvement in future earnings valuation as indicated by the decline in its forward P/E and a marginal uplift in expected revenue growth. What's in the News Board meeting scheduled to consider investment in a subsidiary company.
User avatar
Neues Narrative • Feb 18

Partnerships With IKEA And Karran USA Will Drive Global Expansion In Kitchen Solutions

Carysil's global expansion and strategic partnerships in the U.S. are expected to significantly drive revenue growth and increase market presence.

Gewinn- und Umsatzwachstumsprognosen

BSE:524091 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
DatumUmsatzGewinneFreier CashflowBargeld aus operativen TätigkeitenDurchschn. Anz. Analysten
3/31/202812,6611,3904911,2443
3/31/202711,1001,1504761,1481
3/31/20269,240982-281,087N/A
12/31/20258,944897N/AN/AN/A
9/30/20258,750811203817N/A
6/30/20258,414707N/AN/AN/A
3/31/20258,156637129602N/A
12/31/20248,019608N/AN/AN/A
9/30/20247,868635-1,289-452N/A
6/30/20247,433622N/AN/AN/A
3/31/20246,838579-397534N/A
12/31/20236,388548N/AN/AN/A
9/30/20235,886515207812N/A
6/30/20235,642453N/AN/AN/A
3/31/20235,939524133712N/A
12/31/20225,872564N/AN/AN/A
9/30/20225,77561628737N/A
6/30/20225,577700N/AN/AN/A
3/31/20224,839648-256516N/A
12/31/20214,456614N/AN/AN/A
9/30/20214,05156344659N/A
6/30/20213,613480N/AN/AN/A
3/31/20213,09739189454N/A
12/31/20202,734300N/AN/AN/A
9/30/20202,591247243402N/A
6/30/20202,542209N/AN/AN/A
3/31/20202,762221102301N/A
12/31/20192,772223N/AN/AN/A
9/30/20192,662186N/A286N/A
6/30/20192,594187N/AN/AN/A
3/31/20192,516172N/A237N/A
12/31/20182,370155N/AN/AN/A
9/30/20182,226143N/AN/AN/A
6/30/20182,128126N/AN/AN/A
3/31/20181,965120N/A156N/A
12/31/20171,877117N/AN/AN/A
9/30/20171,806106N/AN/AN/A
6/30/20171,79299N/AN/AN/A
3/31/20171,81073N/A57N/A
12/31/20161,89490N/AN/AN/A
9/30/20161,907101N/AN/AN/A
6/30/20161,79694N/AN/AN/A
3/31/20161,738109N/A106N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: 524091Das prognostizierte Gewinnwachstum (17.4% pro Jahr) liegt über der Sparquote (6.9%).

Ertrag vs. Markt: 524091Die Erträge des Unternehmens (17.4% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16.3% pro Jahr).

Hohe Wachstumserträge: 524091Die Erträge des Unternehmens werden voraussichtlich steigen, jedoch nicht deutlich.

Einnahmen vs. Markt: 524091Die Einnahmen des Unternehmens (15.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (11.1% pro Jahr).

Hohe Wachstumseinnahmen: 524091Die Einnahmen des Unternehmens (15.5% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: 524091Die Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17.4%).

Wachstumsunternehmen entdecken

7D

1Y

7D

1Y

7D

1Y

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/07/15 08:25
Aktienkurs zum Tagesende2026/07/15 00:00
Gewinne2026/03/31
Jährliche Einnahmen2026/03/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Details zum Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite; außerdem bieten wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf Youtube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

Carysil Limited wird von 7 Analysten beobachtet. 3 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
Rishab BothraAnand Rathi Shares and Stock Brokers Limited
null nullAnand Rathi Shares and Stock Brokers Limited
Vyom ChhedaBP Wealth Management Private Limited